Bayer Receives FDA Priority Review for Asundexian in Stroke Prevention
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has accepted its new drug application with priority review status for asundexian, an oral FXIa inhibitor aimed at preventing secondary strokes in non-cardioembolic ischemic stroke patients.
